AMB302/GQ1011, an antibody-drug conjugate (ADC) with TopoI shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion

ByeongkwI Min1, Befei Fan2, Hye Jin Kim3, Sangwook Kim4, Lily Shi5, Cao Lv6, Yajun Sun7, Nam-Gu Her1, Paul Song8, Gang Qin2 and Do-Hyun Nam1,3
1 Amedbio Inc., Seoul 08585, Republic of Korea, 2 GeneQuantum Healthcare Suzhou Co., Ltd., Suzhou, China, 3 Samsung Medical Center, Seoul 06351, Republic of Korea

Abstract # 2634

Background: FGFR3-TACC3 (FGFR3-TACC3) fusion promotes cancer stem cell-like plasticity and the tumorigenic potential of glioblastoma and bladder cancers. While several ADCs have been reported to show potent antitumor activity in glioblastoma and bladder cancer, AMB302/GQ1011 has demonstrated excellent tumor selectivity for FGFR3-TACC3 fusion positive models.

3 RESULTS

AMB302/GQ1011 specifically binds to FGFR3 and induces robust internalization and ADC conjugate killer effects in FGFR3+ tumor models.

AMB302/GQ1011 shows excellent antitumor efficacy in vivo COX6 models with various FGFR3-TACC3 fusion-positive tumors.

AMB302/GQ11 shows better in vivo anti-tumor efficacy than Compassor's ADC

AMB302/GQ1011 shows better in vivo anti-tumor efficacy than Compassor's ADC

Figure 1. AMB302/GQ1011 demonstrates superior antitumor activity compared to Compassor's ADC in the RT112 bladder cancer model.

Figure 2. AMB302/GQ1011 shows significantly increased in vivo antitumor efficacy compared to Compassor's ADC in the RT112 bladder cancer model.

Figure 3. AMB302/GQ1011 demonstrates significant antitumor activity compared to Compassor's ADC in the RT112 bladder cancer model.

Figure 4. AMB302/GQ1011 shows a superior anti-tumor effect against FGFR3 positive (RT112) tumors compared to Compassor's ADC.

Figure 5. In a comprehensive study, AMB302/GQ1011 significantly increased in vivo antitumor efficacy compared to Compassor's ADC. The result suggests that AMB302/GQ1011 is a potent strategy to induce a potent and durable anti-tumor response in vivo.

Figure 6. AMB302/GQ1011 exhibits high tumor localization in syngeneic mouse models.

Figure 7. AMB302/GQ1011 demonstrates high tumor-targeting efficiency in syngeneic mouse models.

Figure 8. AMB302/GQ1011 exhibits a strong antitumor response in vivo COX6 models with various FGFR3-TACC3 fusion-positive tumors.

Figure 9. AMB302/GQ1011 shows an excellent antitumor response in vivo COX6 models with various FGFR3-TACC3 fusion-positive tumors.

Figure 10. AMB302/GQ1011 exhibits a strong antitumor response in vivo COX6 models with various FGFR3-TACC3 fusion-positive tumors.